Espinosa Neuroscience Institute

01/06/2026

01/06/2026

🎉 Welcome to the Team! 🎉

We are proud to welcome Dr. Lisa I. Banchik, MD to Espinosa Neuroscience Institute.

Dr. Banchik brings exceptional clinical expertise with a special focus on pain management, neuropsychiatric disorders, and complex neurological conditions. Her compassionate, patient-centered approach and depth of experience further strengthen our mission to provide comprehensive, cutting-edge neurological care.

Please join us in giving Dr. Banchik a warm welcome—we are excited for the expertise and impact she will bring to our patients and our team.

💙🧠

Patricio Sebastian Espinosa

12/24/2025

Merry Christmas from all of us at Espinosa Neuroscience Institute 🎄
We are deeply grateful to our patients, families, partners, and dedicated team for your trust and support throughout the year. May this holiday season bring you peace, health, and meaningful moments with those you love.
Wishing you a joyful Christmas and a healthy, successful New Year.

Patricio Sebastian Espinosa
International Neurology
Espinosa Neuroscience Institute
Catedra Neurociencias

12/23/2025

Happy to receive the Neuro award from ChatGPT Community
Patricio Sebastian Espinosa

AI is helping healthcare and everyday work achieve new frontiers!

The best is yet to come!

12/17/2025

🚨 Retatrutide achieved an average weight loss of 28.7% - Anti-Obesity Therapy Is Not Incremental Anymore — It’s Transformational

Three days ago, results from the TRIUMPH-4 trial were released.

Patients with obesity and knee osteoarthritis treated with retatrutide 12 mg achieved an average weight loss of 28.7% at 68 weeks.

Let that sink in.

🔹 This level of weight loss approaches bariatric surgery outcomes
🔹 For knee osteoarthritis, this may translate into less pain, improved mobility, and delayed joint replacement
🔹 Highlights the power of triple-agonist therapy (GLP-1 / GIP / Glucagon) over prior generations

We are clearly entering a new era where medical therapy may rival surgical intervention for obesity-related disease.

📉 Obesity is no longer “lifestyle only.”
📈 The science has caught up.


Patricio Sebastian Espinosa

12/16/2025

GLP-1–Based Weight Loss: The Evolution of Obesity Treatment

📉 Average Weight Reduction in Obesity Trials

• Semaglutide (GLP-1): ~15%
• Tirzepatide (GLP-1 + GIP): ~22.5%
• Retatrutide (GLP-1 + GIP + Glucagon): ~28.7%

This is not incremental progress — this is therapeutic evolution.

As GLP-1–based therapies advance from single → dual → triple agonists, outcomes are now approaching surgical-level weight loss for many patients.

Obesity is a chronic disease, and GLP-1 science is reshaping how we treat it.

—
Espinosa Neuroscience Institute & Wellness Center


Patricio Sebastian Espinosa
International Neurology Foundation

12/14/2025

🧠 Botox for Migraine: What the Science Shows

PRECLUDE Study Takeaway

The PRECLUDE trial demonstrated that onabotulinumtoxinA (Botox®) does NOT provide meaningful benefit for episodic migraine
➡️ defined as < 15 headache days per month

🔍 Key Point
• Botox is effective for chronic migraine (≥15 headache days/month)
• Botox is NOT supported for episodic migraine based on high-quality clinical data

📊 Why this matters
Using the right treatment for the right patient:
• Improves outcomes
• Avoids unnecessary procedures
• Ensures evidence-based care

At Espinosa Neuroscience Institute & Wellness Center, we tailor migraine treatment using science—not trends.

📍 Chronic migraine? Botox may help
📍 Episodic migraine? Other therapies are more effective



Patricio Sebastian Espinosa

12/14/2025

🔬 Alzheimer’s Drug Update: Not Ready for Prime Time

GLP-1 therapy for Alzheimer’s disease just faced a major setback.

Novo Nordisk announced that the large Phase 3 EVOKE & EVOKE+ trials of oral semaglutide (Rybelsus) in early-stage Alzheimer’s disease failed to slow memory or cognitive decline compared with placebo.

✔️ The drug was safe
✔️ Some biomarkers improved (including tau-related markers)
❌ But clinical outcomes did not improve

Because the trials missed their primary endpoints, further development for Alzheimer’s has been discontinued.

This is an important reminder:
Biomarker changes ≠ meaningful clinical benefit.
Until therapies clearly slow cognitive decline, they are not ready for prime time.

We must continue to demand rigorous, outcome-driven science for our patients and families affected by Alzheimer’s disease.

— Patricio S. Espinosa, MD
Neurology | Neurodegenerative Disease


Patricio Sebastian Espinosa
International Neurology Foundation

12/14/2025

🧠 Anti-Tau Therapy: Not Ready for Prime Time

The Phase 2 Auτonomy study evaluating an anti-tau monoclonal antibody in early Alzheimer’s disease was recently discontinued after failing to demonstrate a statistically significant slowing of clinical decline.

While disappointing, this outcome reinforces an important reality in Alzheimer’s research: tau-targeted therapies are not yet ready for clinical prime time.

Despite a compelling biological rationale and sophisticated biomarker-guided trial designs, translating tau modulation into meaningful clinical benefit remains elusive. For now, anti-tau approaches are unlikely to become effective disease-modifying treatments in the near future.

Science moves forward through rigorous testing—successes and failures alike. Each study helps refine our understanding of this extraordinarily complex disease.

11/27/2025

🍁 Happy Thanksgiving from the Espinosa Neuroscience Institute 🍁

Today, we pause with gratitude for each of our patients, families, and caregivers who place their trust in us every day.
Your strength, resilience, and partnership inspire our entire team, and we are honored to be part of your care and your journey.

As we celebrate this season of thanks, we want you to know how deeply we appreciate you.
From our ENI family to yours — we wish you a day filled with peace, connection, and gratitude.

Thank you for being part of the ENI community.
Warm Thanksgiving wishes to you and your loved ones. 🧡🦃

— Espinosa Neuroscience Institute
Patricio Sebastian Espinosa